These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 35787739)

  • 21. Cytokeratin 5/6 expression in bladder cancer: association with clinicopathologic parameters and prognosis.
    Hashmi AA; Hussain ZF; Irfan M; Edhi MM; Kanwal S; Faridi N; Khan A
    BMC Res Notes; 2018 Mar; 11(1):207. PubMed ID: 29587848
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bladder Tumor Subtype Commitment Occurs in Carcinoma
    Wullweber A; Strick R; Lange F; Sikic D; Taubert H; Wach S; Wullich B; Bertz S; Weyerer V; Stoehr R; Breyer J; Burger M; Hartmann A; Strissel PL; Eckstein M
    Cancer Res; 2021 Mar; 81(6):1552-1566. PubMed ID: 33472889
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Invasive urothelial carcinoma with chordoid features or abundant myxoid stroma: A reappraisal of morphologic spectrum and risk stratification based on molecular classification.
    Kim JM; Choi E; Sung SH; Kang H; Park S
    Pathol Res Pract; 2023 Nov; 251():154839. PubMed ID: 37801908
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Invasive urothelial carcinoma exhibiting basal cell immunohistochemical markers: A variant of urothelial carcinoma associated with aggressive features.
    Mai KT; Truong LD; Ball CG; Williams P; Flood TA; Belanger EC
    Pathol Res Pract; 2015 Aug; 211(8):610-8. PubMed ID: 26100813
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Micropapillary urothelial carcinoma of urinary bladder displays immunophenotypic features of luminal and p53-like subtypes and is not a variant of adenocarcinoma.
    Yang Y; Kaimakliotis HZ; Williamson SR; Koch MO; Huang K; Barboza MP; Zhang S; Wang M; Idrees MT; Grignon DJ; Eble JN; Baldridge LA; Cheng L
    Urol Oncol; 2020 May; 38(5):449-458. PubMed ID: 31740332
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunohistochemical Expression of Claudin-1 and Claudin-4 in Urothelial Carcinoma of the Urinary Bladder.
    Elsayed AM; Mahmoud EI; Salem MM; Khairy RA
    Asian Pac J Cancer Prev; 2024 Feb; 25(2):637-646. PubMed ID: 38415551
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nested Variant of Urothelial Carcinoma Is a Luminal Bladder Tumor With Distinct Coexpression of the Basal Marker Cytokeratin 5/6.
    Johnson SM; Khararjian A; Legesse TB; Khani F; Robinson BD; Epstein JI; Wobker SE
    Am J Clin Pathol; 2021 Mar; 155(4):588-596. PubMed ID: 33118597
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased co-expression of stromal HHLA2 and fibroblast activation protein in upper tract urothelial carcinoma.
    Nishihara D; Kijima T; Arai K; Kamai T
    Int Urol Nephrol; 2023 Apr; 55(4):867-874. PubMed ID: 36598731
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Micropapillary variant of urothelial carcinoma of the urinary bladder; a clinicopathological and immunohistochemical study.
    Samaratunga H; Khoo K
    Histopathology; 2004 Jul; 45(1):55-64. PubMed ID: 15228444
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of luminal and basal subtype in prognosis of high-grade non muscle invasive urothelial carcinoma.
    Pérez-Montiel D; Olivares-Mundo A; Jiménez-Ríos MA; Morera CS; Scavuzzo A; Orozco-Mora A; Prada D; Cantú-de León D
    Ann Diagn Pathol; 2023 Apr; 63():152081. PubMed ID: 36680930
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fascin is a predictor for invasiveness and recurrence of urothelial carcinoma of bladder.
    Bi J; Chen X; Zhang Y; Li B; Sun J; Shen H; Kong C
    Urol Oncol; 2012 Sep; 30(5):688-94. PubMed ID: 20888270
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Heat-shock protein 70-2 (HSP70-2) expression in bladder urothelial carcinoma is associated with tumour progression and promotes migration and invasion.
    Garg M; Kanojia D; Seth A; Kumar R; Gupta A; Surolia A; Suri A
    Eur J Cancer; 2010 Jan; 46(1):207-15. PubMed ID: 19914824
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cancer Associated Fibroblasts in Stage I-IIIA NSCLC: Prognostic Impact and Their Correlations with Tumor Molecular Markers.
    Kilvaer TK; Khanehkenari MR; Hellevik T; Al-Saad S; Paulsen EE; Bremnes RM; Busund LT; Donnem T; Martinez IZ
    PLoS One; 2015; 10(8):e0134965. PubMed ID: 26252379
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Best practices recommendations in the application of immunohistochemistry in the bladder lesions: report from the International Society of Urologic Pathology consensus conference.
    Amin MB; Trpkov K; Lopez-Beltran A; Grignon D;
    Am J Surg Pathol; 2014 Aug; 38(8):e20-34. PubMed ID: 25029121
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Micropapillary urothelial carcinoma: evaluation of HER2 status and immunohistochemical characterization of the molecular subtype.
    Zinnall U; Weyerer V; Compérat E; Camparo P; Gaisa NT; Knuechel-Clarke R; Perren A; Lugli A; Toma M; Baretton G; Kristiansen G; Wirtz RM; Cheng L; Wullich B; Stoehr R; Hartmann A; Bertz S
    Hum Pathol; 2018 Oct; 80():55-64. PubMed ID: 29885409
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Basal-subtype bladder tumours show a 'hot' immunophenotype.
    Hodgson A; Liu SK; Vesprini D; Xu B; Downes MR
    Histopathology; 2018 Nov; 73(5):748-757. PubMed ID: 29947424
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunohistochemistry subtyping of urothelial carcinoma is feasible in the daily practice.
    Queipo FJ; Unamunzaga GM; Negro BF; Fuertes SG; Cortés MÁ; Tejedor EC; Mañas CMB; Ariño AB; Sjödahl G; Beorlegui C
    Virchows Arch; 2022 Aug; 481(2):191-200. PubMed ID: 35731280
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FOXA1 and CK14 as markers of luminal and basal subtypes in histologic variants of bladder cancer and their associated conventional urothelial carcinoma.
    Warrick JI; Kaag M; Raman JD; Chan W; Tran T; Kunchala S; Shuman L; DeGraff D; Chen G
    Virchows Arch; 2017 Sep; 471(3):337-345. PubMed ID: 28721490
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Distinct genetic alterations and luminal molecular subtype in nested variant of urothelial carcinoma.
    Weyerer V; Weisser R; Moskalev EA; Haller F; Stoehr R; Eckstein M; Zinnall U; Gaisa NT; Compérat E; Perren A; Keck B; Allory Y; Kristiansen G; Wullich B; Agaimy A; Hartmann A; Bertz S
    Histopathology; 2019 Dec; 75(6):865-875. PubMed ID: 31348552
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Weighted gene co-expression network analysis can sort cancer-associated fibroblast-specific markers promoting bladder cancer progression.
    Liu B; Zhan Y; Chen X; Hu X; Wu B; Pan S
    J Cell Physiol; 2021 Feb; 236(2):1321-1331. PubMed ID: 32657439
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.